Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03844256
Title A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (CRIMI)
Acronym CRIMI
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD


No variant requirements are available.